Image may be NSFW.
Clik here to view.
Johnson & Johnson‘s (NYSE:JNJ) Janssen Biotech said today that it agreed to acquire BeneVir Biopharm and its T-Stealth oncolytic virus platform.
The privately-held biopharmaceutical company engineers cancer-killing viruses that are designed to infect and destroy cancer cells. Janssen plans to develop BeneVir’s preclinical candidates for the treatment of solid tumor cancers.
Get the full story at our sister site, Drug Delivery Business News.
The post J&J’s Janssen acquires cancer-killing virus tech appeared first on MassDevice.
